Our findings suggest that PCA3 may not be a complete replacement for PSA as the appropriate choice of test for prostate cancer especially in the Ghanaian population but may however serve as a complimentary diagnostic biomarker which would be very beneficial in the management and treatment of malignant and nonmalignant prostate conditions. The gene discussed is KLK3; the disease is prostate carcinoma.